Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Integrating Traditional Ecological Knowledge and Remote Sensing for Monitoring Rangeland Dynamics in the Altai Mountain Region.

Paltsyn MY, Gibbs JP, Mountrakis G.

Environ Manage. 2019 Jul;64(1):40-51. doi: 10.1007/s00267-018-01135-6. Epub 2019 Jun 3.

PMID:
31161233
2.

Migration triggers in a large herbivore: Galápagos giant tortoises navigating resource gradients on volcanoes.

Bastille-Rousseau G, Yackulic CB, Gibbs JP, Frair JL, Cabrera F, Blake S.

Ecology. 2019 Jun;100(6):e02658. doi: 10.1002/ecy.2658. Epub 2019 Apr 18.

PMID:
30998258
3.

Genetically informed captive breeding of hybrids of an extinct species of Galapagos tortoise.

Quinzin MC, Sandoval-Castillo J, Miller JM, Beheregaray LB, Russello MA, Hunter EA, Gibbs JP, Tapia W, Villalva F, Caccone A.

Conserv Biol. 2019 Mar 22. doi: 10.1111/cobi.13319. [Epub ahead of print]

PMID:
30901116
4.

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.

Lee E, Gibbs JP, Emery MG, Block G, Wasserman SM, Hamilton L, Kasichayanula S, Hanafin P, Somaratne R, Egbuna O.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):281-289. doi: 10.1002/cpdd.650. Epub 2019 Jan 24.

5.

Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse.

Shebley M, Menon RM, Gibbs JP, Dave N, Kim SY, Marroum PJ.

J Clin Pharmacol. 2019 May;59(5):625-637. doi: 10.1002/jcph.1359. Epub 2018 Dec 18. Review.

6.

Giant tortoise genomes provide insights into longevity and age-related disease.

Quesada V, Freitas-Rodríguez S, Miller J, Pérez-Silva JG, Jiang ZF, Tapia W, Santiago-Fernández O, Campos-Iglesias D, Kuderna LFK, Quinzin M, Álvarez MG, Carrero D, Beheregaray LB, Gibbs JP, Chiari Y, Glaberman S, Ciofi C, Araujo-Voces M, Mayoral P, Arango JR, Tamargo-Gómez I, Roiz-Valle D, Pascual-Torner M, Evans BR, Edwards DL, Garrick RC, Russello MA, Poulakakis N, Gaughran SJ, Rueda DO, Bretones G, Marquès-Bonet T, White KP, Caccone A, López-Otín C.

Nat Ecol Evol. 2019 Jan;3(1):87-95. doi: 10.1038/s41559-018-0733-x. Epub 2018 Dec 3.

7.

Population genomics through time provides insights into the consequences of decline and rapid demographic recovery through head-starting in a Galapagos giant tortoise.

Jensen EL, Edwards DL, Garrick RC, Miller JM, Gibbs JP, Cayot LJ, Tapia W, Caccone A, Russello MA.

Evol Appl. 2018 Aug 13;11(10):1811-1821. doi: 10.1111/eva.12682. eCollection 2018 Dec.

8.

Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions.

Clements JD, Perez Ruixo JJ, Gibbs JP, Doshi S, Perez Ruixo C, Melhem M.

CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):771-779. doi: 10.1002/psp4.12354. Epub 2018 Oct 15.

9.

Genome-Wide Assessment of Diversity and Divergence Among Extant Galapagos Giant Tortoise Species.

Miller JM, Quinzin MC, Edwards DL, Eaton DAR, Jensen EL, Russello MA, Gibbs JP, Tapia W, Rueda D, Caccone A.

J Hered. 2018 Aug 24;109(6):611-619. doi: 10.1093/jhered/esy031.

PMID:
29986032
10.

Community involvement works where enforcement fails: conservation success through community-based management of Amazon river turtle nests.

Norris D, Michalski F, Gibbs JP.

PeerJ. 2018 Jun 1;6:e4856. doi: 10.7717/peerj.4856. eCollection 2018.

11.

Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.

Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP.

J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16.

PMID:
29768954
12.

Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia.

Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7.

13.

Author Correction: Identification of Genetically Important Individuals of the Rediscovered Floreana Galápagos Giant Tortoise (Chelonoidis elephantopus) Provides Founders for Species Restoration Program.

Miller JM, Quinzin MC, Poulakakis N, Gibbs JP, Beheregaray LB, Garrick RC, Russello MA, Ciofi C, Edwards DL, Hunter EA, Tapia W, Rueda D, Carrión J, Valdivieso AA, Caccone A.

Sci Rep. 2018 Mar 12;8(1):4568. doi: 10.1038/s41598-018-22519-y.

14.

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor.

Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP.

Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. Review.

15.

Beyond harm's reach? Submersion of river turtle nesting areas and implications for restoration actions after Amazon hydropower development.

Norris D, Michalski F, Gibbs JP.

PeerJ. 2018 Jan 8;6:e4228. doi: 10.7717/peerj.4228. eCollection 2018.

16.

Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development.

Gibbs JP, Menon R, Kasichayanula S.

Clin Pharmacol Ther. 2018 Feb;103(2):196-198. doi: 10.1002/cpt.897. Epub 2017 Nov 6.

17.

Identification of Genetically Important Individuals of the Rediscovered Floreana Galápagos Giant Tortoise (Chelonoidis elephantopus) Provide Founders for Species Restoration Program.

Miller JM, Quinzin MC, Poulakakis N, Gibbs JP, Beheregaray LB, Garrick RC, Russello MA, Ciofi C, Edwards DL, Hunter EA, Tapia W, Rueda D, Carrión J, Valdivieso AA, Caccone A.

Sci Rep. 2017 Sep 13;7(1):11471. doi: 10.1038/s41598-017-11516-2. Erratum in: Sci Rep. 2018 Mar 12;8(1):4568.

18.

Evolutionary response to global change: Climate and land use interact to shape color polymorphism in a woodland salamander.

Cosentino BJ, Moore JD, Karraker NE, Ouellet M, Gibbs JP.

Ecol Evol. 2017 Jun 12;7(14):5426-5434. doi: 10.1002/ece3.3118. eCollection 2017 Jul.

19.

Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

Chen P, Narayanan A, Wu B, Gisleskog PO, Gibbs JP, Chow AT, Melhem M.

Clin Pharmacokinet. 2018 Jan;57(1):71-85. doi: 10.1007/s40262-017-0550-4.

PMID:
28508378
20.

Scale-dependence in polychlorinated biphenyl (PCB) exposure effects on waterbird habitat occupancy.

Gibbs JP, Rouhani S, Shams L.

Ecotoxicology. 2017 Aug;26(6):762-771. doi: 10.1007/s10646-017-1807-2. Epub 2017 Apr 25.

PMID:
28444511
21.

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.

Desai NR, Giugliano RP, Wasserman SM, Gibbs JP, Liu T, Scott R, Sabatine MS.

JAMA Cardiol. 2017 May 1;2(5):556-560. doi: 10.1001/jamacardio.2016.5395.

22.

SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum.

Xie F, Emery MG, Gibbs JP, Rock DA, Rock BM.

Bioanalysis. 2016 Dec;8(24):2551-2563.

PMID:
27884075
23.

Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).

Gibbs JP, Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, Gibbs MA, Somaratne R, Wasserman SM, Blom D.

J Clin Pharmacol. 2017 May;57(5):616-626. doi: 10.1002/jcph.840. Epub 2016 Nov 15.

24.

Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.

Gibbs JP, Slatter JG, Egbuna O, Geller M, Hamilton L, Dias CS, Xu RY, Johnson J, Wasserman SM, Emery MG.

J Clin Pharmacol. 2017 Apr;57(4):513-523. doi: 10.1002/jcph.832. Epub 2016 Oct 26.

25.

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.

Chen P, Olsson Gisleskog P, Perez-Ruixo JJ, Xiao J, Wilkins J, Narayanan A, Gibbs JP, Melhem M.

CPT Pharmacometrics Syst Pharmacol. 2016 Sep;5(9):484-94. doi: 10.1002/psp4.12106. Epub 2016 Sep 17.

26.

Impact of forestry practices at a landscape scale on the dynamics of amphibian populations.

Harper EB, Patrick DA, Gibbs JP.

Ecol Appl. 2015 Dec;25(8):2271-84.

PMID:
26910954
27.

Description of a New Galapagos Giant Tortoise Species (Chelonoidis; Testudines: Testudinidae) from Cerro Fatal on Santa Cruz Island.

Poulakakis N, Edwards DL, Chiari Y, Garrick RC, Russello MA, Benavides E, Watkins-Colwell GJ, Glaberman S, Tapia W, Gibbs JP, Cayot LJ, Caccone A.

PLoS One. 2015 Oct 21;10(10):e0138779. doi: 10.1371/journal.pone.0138779. eCollection 2015.

28.

Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.

Gow JM, Tsuji WH, Williams GJ, Mytych D, Sciberras D, Searle SL, Mant T, Gibbs JP.

Arthritis Res Ther. 2015 Oct 8;17:282. doi: 10.1186/s13075-015-0797-9.

29.

Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations.

Mould DR, Walz AC, Lave T, Gibbs JP, Frame B.

CPT Pharmacometrics Syst Pharmacol. 2015 Jan;4(1):e00016. doi: 10.1002/psp4.16. Epub 2015 Jan 21.

30.

Naturally rare versus newly rare: demographic inferences on two timescales inform conservation of Galápagos giant tortoises.

Garrick RC, Kajdacsi B, Russello MA, Benavides E, Hyseni C, Gibbs JP, Tapia W, Caccone A.

Ecol Evol. 2015 Feb;5(3):676-94. doi: 10.1002/ece3.1388. Epub 2015 Jan 13.

31.

Conservation: Giant tortoises hatch on Galapagos island.

Aguilera WT, Málaga J, Gibbs JP.

Nature. 2015 Jan 15;517(7534):271. doi: 10.1038/517271a. No abstract available.

PMID:
25592525
32.

Demographic outcomes and ecosystem implications of giant tortoise reintroduction to Española Island, Galapagos.

Gibbs JP, Hunter EA, Shoemaker KT, Tapia WH, Cayot LJ.

PLoS One. 2014 Oct 28;9(10):e110742. doi: 10.1371/journal.pone.0110742. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e114048.

33.

Lineage fusion in Galápagos giant tortoises.

Garrick RC, Benavides E, Russello MA, Hyseni C, Edwards DL, Gibbs JP, Tapia W, Ciofi C, Caccone A.

Mol Ecol. 2014 Nov;23(21):5276-90. doi: 10.1111/mec.12919. Epub 2014 Oct 4.

34.

Preclinical development of AMG 139, a human antibody specifically targeting IL-23.

Köck K, Pan WJ, Gow JM, Horner MJ, Gibbs JP, Colbert A, Goletz TJ, Newhall KJ, Rees WA, Sun Y, Zhang Y, O'Neill JC, Umble-Romero AN, Prokop SP, Krill CD, Som L, Buntich SA, Trimble MW, Tsuji WH, Towne JE.

Br J Pharmacol. 2015 Jan;172(1):159-72. doi: 10.1111/bph.12904. Epub 2014 Dec 15.

35.

Disambiguating the minimum viable population concept: response to Reed and McCoy.

Shoemaker KT, Breisch AR, Jaycox JW, Gibbs JP.

Conserv Biol. 2014 Jun;28(3):871-3. doi: 10.1111/cobi.12273. Epub 2014 Mar 11. No abstract available.

PMID:
24617998
36.

Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed First-in-Patient Study Designs in Psoriasis.

Dodds MG, Salinger DH, Mandema J, Gibbs JP, Gibbs MA.

CPT Pharmacometrics Syst Pharmacol. 2013 Jul 24;2:e58. doi: 10.1038/psp.2013.32.

37.

Equivalency of Galápagos giant tortoises used as ecological replacement species to restore ecosystem functions.

Hunter EA, Gibbs JP, Cayot LJ, Tapia W.

Conserv Biol. 2013 Aug;27(4):701-9. doi: 10.1111/cobi.12038. Epub 2013 Mar 26.

PMID:
23530938
38.

Recovery of a nearly extinct Galápagos tortoise despite minimal genetic variation.

Milinkovitch MC, Kanitz R, Tiedemann R, Tapia W, Llerena F, Caccone A, Gibbs JP, Powell JR.

Evol Appl. 2013 Feb;6(2):377-83. doi: 10.1111/eva.12014. Epub 2012 Oct 10.

39.

Reexamining the minimum viable population concept for long-lived species.

Shoemaker KT, Breisch AR, Jaycox JW, Gibbs JP.

Conserv Biol. 2013 Jun;27(3):542-51. doi: 10.1111/cobi.12028. Epub 2013 Mar 4.

PMID:
23458501
40.

Vegetation dynamics drive segregation by body size in Galapagos tortoises migrating across altitudinal gradients.

Blake S, Yackulic CB, Cabrera F, Tapia W, Gibbs JP, Kümmeth F, Wikelski M.

J Anim Ecol. 2013 Mar;82(2):310-21. doi: 10.1111/1365-2656.12020. Epub 2012 Nov 21.

PMID:
23171344
41.

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.

Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA.

J Am Coll Cardiol. 2012 Nov 6;60(19):1888-98. doi: 10.1016/j.jacc.2012.08.986. Epub 2012 Oct 17.

42.

Genetic rediscovery of an 'extinct' Galápagos giant tortoise species.

Garrick RC, Benavides E, Russello MA, Gibbs JP, Poulakakis N, Dion KB, Hyseni C, Kajdacsi B, Márquez L, Bahan S, Ciofi C, Tapia W, Caccone A.

Curr Biol. 2012 Jan 10;22(1):R10-1. doi: 10.1016/j.cub.2011.12.004. No abstract available.

43.

Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

Gibbs JP, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, Gibbs MA.

J Clin Pharmacol. 2012 Oct;52(10):1494-505. Epub 2011 Dec 12.

PMID:
22162539
44.

Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.

Greene RJ, Tu H, Gibbs JP, Greg Slatter J.

Xenobiotica. 2011 Nov;41(11):945-57. doi: 10.3109/00498254.2011.597455. Epub 2011 Aug 25.

PMID:
21867423
45.

Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.

Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA.

Clin Pharmacokinet. 2011 Feb;50(2):131-42. doi: 10.2165/11537430-000000000-00000.

PMID:
21241072
46.

Road deicing salt irreversibly disrupts osmoregulation of salamander egg clutches.

Karraker NE, Gibbs JP.

Environ Pollut. 2011 Mar;159(3):833-5. doi: 10.1016/j.envpol.2010.11.019. Epub 2010 Dec 13.

PMID:
21147507
47.

Prediction of exposure-response relationships to support first-in-human study design.

Gibbs JP.

AAPS J. 2010 Dec;12(4):750-8. doi: 10.1208/s12248-010-9236-7. Epub 2010 Oct 22. Review.

48.

Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.

Gibbs JP, Emery MG, McCaffery I, Smith B, Gibbs MA, Akrami A, Rossi J, Paweletz K, Gastonguay MR, Bautista E, Wang M, Perfetti R, Daniels O.

J Clin Pharmacol. 2011 Jun;51(6):830-41. doi: 10.1177/0091270010374470. Epub 2010 Jul 27.

PMID:
20663992
49.

DNA from the past informs ex situ conservation for the future: an "extinct" species of Galápagos tortoise identified in captivity.

Russello MA, Poulakakis N, Gibbs JP, Tapia W, Benavides E, Powell JR, Caccone A.

PLoS One. 2010 Jan 13;5(1):e8683. doi: 10.1371/journal.pone.0008683.

50.

Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings.

Amore BM, Gibbs JP, Emery MG.

Comb Chem High Throughput Screen. 2010 Feb;13(2):207-18. Review.

PMID:
20053166

Supplemental Content

Loading ...
Support Center